2seventy bio News

Buy Rating Affirmed for 2seventy Bio on Strong Growth Prospects and Financial Stability

TipRanksMay 10 00:33

2seventy bio | 10-Q: Quarterly report

Futu NewsMay 9 15:10 · Announcements

2seventy Bio Is Maintained at Buy by Canaccord Genuity

2seventy Bio Is Maintained at Buy by Canaccord Genuity

Dow JonesMay 9 14:18

Canadian Investment Banking Group: Maintaining the 2seventy bio (TSVT.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $12.00 to $11.00.

Canadian Investment Banking Group: Maintaining the 2seventy bio (TSVT.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $12.00 to $11.00.

Zhitong FinanceMay 9 14:10

Canaccord Genuity Maintains Buy on 2seventy Bio, Lowers Price Target to $11

Canaccord Genuity analyst John Newman maintains 2seventy bio (NASDAQ:TSVT) with a Buy and lowers the price target from $12 to $11.

BenzingaMay 9 14:08

2seventy Bio Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/09/2024 148.31% Canaccord Genuity $12 → $11 Maintains Buy 04/08/2024 170.88% Citigroup $9 → $12 Maintai

BenzingaMay 9 14:06

2seventy Bio, Inc. (NASDAQ:TSVT) Q1 2024 Earnings Call Transcript

Yahoo FinanceMay 9 12:21

Q1 2024 2Seventy Bio Inc Earnings Call

Yahoo FinanceMay 8 21:23

2seventy Bio, Inc. (TSVT) Q1 2024 Earnings Call Transcript

2seventy bio, Inc. (TSVT) Q1 2024 Earnings Call Transcript

Earnings Call TranscriptsMay 8 14:15

2seventy Bio Inc (TSVT) Q1 2024 Earnings: Misses Revenue Estimates Amid Strategic Realignments

Yahoo FinanceMay 8 07:39

2seventy Bio Q1 Adj $(0.81), Inline, Sales $12.44M Miss $14.08M Estimate

2seventy bio (NASDAQ:TSVT) reported quarterly losses of $(0.81) per share which met the analyst consensus estimate. This is a 25 percent increase over losses of $(1.08) per share from the same period

BenzingaMay 8 06:08

2seventy Bio 1Q Loss $52.7M >TSVT

2seventy Bio 1Q Loss $52.7M >TSVT

Dow JonesMay 8 06:05

2seventy Bio 1Q Rev $12.4M >TSVT

2seventy Bio 1Q Rev $12.4M >TSVT

Dow JonesMay 8 06:05

2seventy Bio 1Q Loss/Shr $1.01 >TSVT

2seventy Bio 1Q Loss/Shr $1.01 >TSVT

Dow JonesMay 8 06:05

Earnings Flash (TSVT) 2SEVENTY BIO Reports Q1 Revenue $12.4M, Vs. Street Est of $14.1M

07:02 AM EDT, 05/08/2024 (MT Newswires) -- Earnings Flash (TSVT) 2SEVENTY BIO Reports Q1 Revenue $12.4M, vs. Street Est of $14.1M

MT NewswiresMay 8 06:02

Press Release: 2seventy Bio Reports First Quarter Financial Results and Recent Operational Progress

2seventy bio Reports First Quarter Financial Results and Recent Operational Progress U.S. FDA Approval of Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines

Dow JonesMay 8 06:02

2seventy Bio to Report First Quarter 2024 Financial Results on May 8, 2024

2seventy bio, Inc. (NASDAQ:TSVT) will announce its first quarter 2024 financial results on Wednesday, May 8, 2024. A conference call and webcast will be held at 8:00 a.m. ET. Participants can access the conference

BusinesswireMay 3 06:00

Leerink Partners Sticks to Their Buy Rating for 2seventy Bio (TSVT)

TipRanksApr 30 01:06

Bristol-Myers Posts Q1 Beat Despite Growth Headwinds

Seeking AlphaApr 25 06:56

FDA Mandates "Boxed Warning" For Bristol Myers, Johnson & Johnson CAR-T-Based Blood Cancer Therapies

Following an investigation announced in November last year, the FDA said on Thursday that it would now require boxed warnings—the highest safety-related caution for medications—for all chimeric antige

BenzingaApr 19 08:28